Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkin’s disease
Keywords:
Proliferating cell nuclear antigen, P53 genes, Proto-oncogene proteins c-mdm2, Hodgkin disease, ImmunohistochemistryAbstract
CONTEXT AND OBJECTIVE: Tumor cells in Hodgkin’s disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins. Correlations between the protein expression grade and clinical data are now important for disease prognosis. DESIGN AND SETTING: This was a retrospective analysis on proliferating cell nuclear antigen (PCNA), p53 and MDM2 (murine double minute-2) expression using immunohistochemistry, on formalinfi xed, paraffi n-embedded tissues from diagnostic biopsies on 51 patients with HD. The study was conducted at the Division of Hematology and Transfusion Medicine, Hospital São Paulo, Universidade Federal de São Paulo. METHODS: Antigen expression was evaluated as the proportions of positive Hodgkin and ReedSternberg (HRS) cells and reactive lymphocytes (L), which were compared using Spearman correlation coeffi cients. The Friedman test was used for comparisons between the markers. The Pearson test was used to investigate associations between marker expression and clinical and laboratory parameters, marrow involvement, complete remission (CR) and overall survival (OS) rates. RESULTS: There was overexpression of antigen proteins in HRS, in relation to L (p < 0.001). In HRS, MDM2 was higher than p53 and PCNA (p < 0.003), while the latter two were equivalent. In L, p53 was lower than MDM2 and PCNA (p < 0.001), while the latter two were equivalent. There was no relationship between protein expression and clinical and laboratory variables or outcome. CONCLUSIONS: PCNA, p53 and MDM2 are tumor markers for HD, but showed no clinical or prognostic signifi cance in our analysis.
Downloads
References
Falini B, Stein H, Pileri S, et al. Expression of lymphoid-associated antigens on Hodgkin’s and Reed-Sternberg cells of Hodgkin’s disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies. Histopathology. 1987;11(12):1229-42.
Hsu SM, Hsu PL. Aberrant expression of T cell and B-cell markers in myelocyte/monocyte/histiocyte-derived lymphoma and leukemia cells. Is the infrequent expression of T/B cell markers sufficient to establish a lymphoid origin from Hodgkin’s Reed-Sternberg cells? Am J Pathol. 1989;134(1):203-12.
Morgan KG, Quirke P, O’Brien CJ, Bird CC. Hodgkin’s disease: a flow cytometric study. J Clin Pathol. 1988;41(4):365-9.
Cossman J. Gene expression analysis of single neoplastic cells and the pathogenesis of Hodgkin’s lymphoma. J Histochem Cytochem. 2001;49(6):799-800.
Spieker T, Kurth J, Kuppers R, Rajewsky K, Bräuninger A, Hansmann ML. Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease. Blood. 2000;96(9):3133-8.
Kuppers R, Sousa AB, Baur AS, Strickler JG, Rajewsky K, Hansmann ML. Common germinal-center B-cell origin of malignant cells in two composite lymphomas, involving classical Hodgkin’s disease and either follicular lymphoma or B-CLL. Mol Med. 2001;7(5):285-92.
Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin’s lymphoma: immunophenotypic and molecular studies. Semin Hematol. 1999;36(3):233-41.
Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1p/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95(6):2084-92.
Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin’s disease provides further evidence for its B-cell origin. Blood. 1999;94(9):3108-13.
Sabattini E, Gerdes J, Gherlinzoni F, et al. Comparison between the monoclonal antibodies Ki-67 and PC10 in 125 malignant lymphomas. J Pathol. 1993;169(4):397-403.
Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol. 1989;134(4):733-9.
Naresh KN, O’Conor GT, Soman CS, et al. A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin’s disease at presentation and relapse. Hum Pathol. 1997;28(5):549-55.
Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351(6326):453-6.
Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppression protein p53 by DNA- damaging agents. Oncogene. 1993;8(2):307-18.
Trümper LH, Brady G, Bagg A, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expres- sion and p53 mutations. Blood. 1993;81(11):3097-115.
Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin’s disease: dissociation between im- munohistochemistry and clinicopathological data. Hum Pathol. 1994;25(5):449-54.
Chilosi M, Doglioni C, Menestrina F, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin’s disease. Blood. 1994;84(12):4295-300.
Elenitoba-Johnson KS, Medeiros LJ, Khorsand J, King TC. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin’s disease. Am J Clin Pathol. 1996;106(6):728-38.
Xerri L, Parc P, Bouabdallah R, Camerlo, J, Hassoun J. PCR- mismatch analysis of p53 gene mutation in Hodgkin’s disease. J Pathol. 1995;175(2):189-94.
Chen WG, Chen YY, Kamel OW, Koo CH, Weiss LM. p53 muta- tions in Hodgkin’s disease. Lab Invest. 1996;75(4):519-27.
Martinez JC, Mateo M, Sanchez-Beato M, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lym- phoid tissue. Comparative study with p53 expression. J Pathol. 1995;177(1):27-34.
Weiss L, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin’s disease. A correlative in situ hybridiza- tion and polymerase chain reaction study. Am J Pathol. 1991;139(6):1259-65.
Tzardi M, Kouvidou C, Panayiotides I, et al. Expression of p53 and mdm-2 proteins in Hodgkin’s Disease. Absence of correla- tion with the presence of Epstein-Barr virus. Anticancer Res. 1996;16(5A):2813-9.
Yuen AR, Horning SJ. Recent advances in Hodgkin’s disease. Curr Opin Hematol. 1996;3(4):273-8.
Hsu SM, Raine L, Fanger K. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29(4):577-80.
Sánchez-Beato M, Piris MA, Martínez-Montero JC, et al. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin’s disease. J Pathol. 1996;180(1):58-64.
Hell K, Lorenzen J, Hansmann ML, Fellbaum C, Busch R, Fischer R. Expression of the proliferating cell nuclear antigen in the different types of Hodgkin’s disease. Am J Clin Pathol. 1993;99(5):508-603.
Schmid C, Sweeney E, Isaacson PG. Proliferating cell nuclear antigen (PCNA) expression in Hodgkin’s disease. J Pathol. 1992;168(1):1-6.
Martinez-Delgado B, Robledo M, Arranz E, et al. Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol. 1997;55(1):1-8.
Niedobitek G, Rowlands DC, Young LS, et al. Overexpression of p53 in Hodgkin’s disease: lack of correlation with Epstein-Barr virus infection. J Pathol. 1993;169(2):207-12.
Smolewski P, Niewiadomska H, Blonski JZ, Robak T, Krykowski E. Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin’s disease. Neoplasma. 1998;45(3):140-7.
Smolewski P, Niewiadomska H, Los E, Robak T. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin’s disease. Int J Oncol. 2000;17(3):603-9.
Smolewski P, Niewiadomska H, Krykowski E, Robak T. Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin’s disease. Neoplasma. 1999;46(4):212-8.
Smoleswski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6(3):1150-60.
Brink AA, Oudejans JJ, van den Brule AJ, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin’s disease: involvement of apoptosis resistance? Mod Pathol. 1998;11(4):376-83.
Montalban C, Abraira V, Morente M, et al. Epstein-Barr virus- latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin’s Disease treated with chemotherapy. Leuk Lymphoma. 2000;39(5-6):563-72.
Murray PG, Billingham LJ, Hassan HT, et al. Effect of Epstein- Barr virus infection on response to chemotherapy and survival in Hodgkin’s disease. Blood. 1999;94(2):442-7.
Spector N, Milito CB, Biasoli I, Luiz RR, Pulcheri W, Morais JC. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin’s lymphoma. Leuk Lymphoma. 2005;46(9):1301-6.
Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin’s lymphoma: a study by the Spanish Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2004;22(9):1664-73.
